



Supplementary Data

Randomized, controlled trial study design



Open-label extension study design



SUPPLEMENTARY FIG. S1. Study designs. ^aBased on the patient's therapeutic response and tolerability, dose could be increased to 30 mg/day by the end of week 2 or at the end of week 3. ^bNo further dose increases were allowed beyond week 3. A single reduction to 15 mg/day was allowed for tolerability in patients taking vilazodone 30 mg/day.